Get the latest news and updates
Kevin Horgan has worked extensively on therapeutics and diagnostics in inflammation and oncology, across both early and late stage development. Most recently he led the development of combination immunotherapies in oncology at Astra Zeneca, prior to joining Seres Therapeutics in October 2018. Seres develops microbiome based therapeutics for infection, inflammatory diseases and cancer. He graduated in medicine from University College Cork in 1982. He completed postgraduate medical training at the Johns Hopkins Hospital in Baltimore, MD, the National Cancer Institute in Bethesda, MD, and UCLA in internal medicine, immunology and gastroenterology. At Merck Research Laboratories, he led the development of Emend® for the prevention of nausea and vomiting associated with cancer chemotherapy.
Leveraging The Gastrointestinal Microbiome For Clinical Benefit
Awareness of the gastrointestinal microbiome as an important determinant of health has recently increased. I will outline an approach for the development of microbiome based therapies that has led to encouraging clinical data in the treatment of ulcerative colitis and optimism for the future of this novel modality in a broad spectrum of settings.
A growing body of evidence suggests that the broader community of gut microbes may influence cancer risk, provide diagnostic insight, shape clinical course, and impact treatment success. Microbiome-directed therapies hold tremendous promise for personalized therapies and improved treatment outcomes.